Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
BioSpace4h
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...
STAT6h
Lilly expands GLP-1 research to hypertension, neuro conditions
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...
Super Bowl Ad Raises Questions About Compounded Versus Branded Obesity Meds
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...
Zacks.com on MSN7h
Pharma Stock Roundup: PFE, LLY, NVO, LLY and AZN's Q4 Earnings Update
This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...
NVO INVESTOR DEADLINE: Novo Nordisk Investors are Alerted to Contact BFA Law before the Imminent March 25 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...
manilatimes13h
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds ...
Hosted on MSN18h
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...